Suppr超能文献

房室折返性心动过速中药物反应的一致性与不一致性

Concordance and discordance of drug responses in atrioventricular reentrant tachycardia.

作者信息

Bauernfeind R A, Swiryn S, Petropoulos A T, Coelho A, Gallastegui J, Rosen K M

出版信息

J Am Coll Cardiol. 1983 Aug;2(2):345-50. doi: 10.1016/s0735-1097(83)80173-9.

Abstract

Whether the results of some drug studies could be used to predict the results of other drug studies was examined during serial electrophysiologic drug testing in patients with sustained atrioventricular reentrant tachycardia. The drugs studied were intravenous propranolol, 0.1 mg/kg; intravenous ouabain, 0.01 mg/kg; the combination of propranolol plus ouabain; intravenous procainamide, 0.75 to 1.5 g; oral quinidine, 1.2 to 2.4 g/day; and oral disopyramide, 0.8 to 1.6 g/day. Response was inability to induce sustained tachycardia after administration of a drug. Responses due to increased anterograde limb refractoriness. Six of 10 patients with response to propranolol plus ouabain versus 0 of 9 patients without response to this combination had response to propranolol alone (p less than 0.01). Seven of 14 patients with response to the combination versus 0 of 9 patients without response to the combination had response to ouabain alone (p less than 0.05). Responses due to increased retrograde limb refractoriness. Eight of 9 patients with response to procainamide versus 2 of 17 patients without response to this drug had response to quinidine (p less than 0.01). There was not a significant relation between response to procainamide and response to disopyramide, or between response to quinidine and response to disopyramide. Anterograde limb versus retrograde limb. There was not a significant relation between response to propranolol plus ouabain and response to any class I drug. In conclusion, there are relations between drug responses during electrophysiologic studies in patients with atrioventricular reentrant tachycardia. Thus, it should be possible to simplify these studies.

摘要

在对持续性房室折返性心动过速患者进行系列电生理药物测试期间,研究了某些药物研究的结果是否可用于预测其他药物研究的结果。所研究的药物包括静脉注射普萘洛尔,0.1mg/kg;静脉注射毒毛花苷K,0.01mg/kg;普萘洛尔加毒毛花苷K的联合用药;静脉注射普鲁卡因胺,0.75至1.5g;口服奎尼丁,1.2至2.4g/天;以及口服丙吡胺,0.8至1.6g/天。反应为给药后不能诱发持续性心动过速。反应是由于前向支不应期延长。对普萘洛尔加毒毛花苷K有反应的10例患者中有6例,而对该联合用药无反应的9例患者中无1例对单独使用普萘洛尔有反应(p<0.01)。对联合用药有反应的14例患者中有7例,而对该联合用药无反应的9例患者中无1例对单独使用毒毛花苷K有反应(p<0.05)。反应是由于逆向支不应期延长。对普鲁卡因胺有反应的9例患者中有8例,而对该药物无反应的17例患者中有2例对奎尼丁有反应(p<0.01)。对普鲁卡因胺的反应与对丙吡胺的反应之间,或对奎尼丁的反应与对丙吡胺的反应之间均无显著关系。前向支与逆向支。对普萘洛尔加毒毛花苷K的反应与对任何I类药物的反应之间无显著关系。总之,房室折返性心动过速患者电生理研究期间的药物反应之间存在关联。因此,简化这些研究应该是可行的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验